|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nicholson AG, Tsao MS, Beasley MB, Borczuk
AC, Brambilla E, Cooper WA, Dacic S, Jain D, Kerr KM, Lantuejoul S,
et al: The 2021 WHO classification of lung tumors: Impact of
advances since 2015. J Thorac Oncol. 17:362–387. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Feng SH and Yang ST: The new 8th TNM
staging system of lung cancer and its potential imaging
interpretation pitfalls and limitations with CT image
demonstrations. Diagn Interv Radiol. 25:270–279. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Blumenthal GM, Bunn PA Jr, Chaft JE,
McCoach CE, Perez EA, Scagliotti GV, Carbone DP, Aerts HJWL, Aisner
DL, Bergh J, et al: Current status and future perspectives on
neoadjuvant therapy in lung cancer. J Thorac Oncol. 13:1818–1831.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Burdett S, Stewart L, Auperin A and Pignon
JP: Chemotherapy in non-small-cell lung cancer: An update of an
individual patient data meta-analysis. J Clin Oncol. 23:924–925;
author reply 925–926. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Duma N, Santana-Davila R and Molina JR:
Non-Small cell lung cancer: Epidemiology, screening, diagnosis, and
treatment. Mayo Clin Proc. 94:1623–1640. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Reck M, Rodríguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: Pembrolizumab versus Chemotherapy for PD-L1-positive
non-small-cell lung cancer. N Engl J Med. 375:1823–1833. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Forde PM, Chaft JE, Smith KN, Anagnostou
V, Cottrell TR, Hellmann MD, Zahurak M, Yang SC, Jones DR,
Broderick S, et al: Neoadjuvant PD-1 blockade in resectable lung
cancer. N Engl J Med. 378:1976–1986. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Alshangiti A, Chandhoke G and Ellis PM:
Antiangiogenic therapies in non-small-cell lung cancer. Curr Oncol.
25 (Suppl 1):S45–S58. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rapisarda A and Melillo G: Role of the
VEGF/VEGFR axis in cancer biology and therapy. Adv Cancer Res.
114:237–267. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Feng L, Wang Z, Jing L, Zhou Z, Shi S,
Deng R, Liu Y and Meng Q: Recombinant human endostatin combined
with chemotherapy for advanced squamous cell lung cancer: A
meta-analysis. World J Surg Oncol. 19:642021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Detterbeck FC, Boffa DJ, Kim AW and Tanoue
LT: The eighth edition lung cancer stage classification. Chest.
151:193–203. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schwartz LH, Litiere S, de Vries E, Ford
R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J,
et al: RECIST 1.1-Update and clarification: From the RECIST
committee. Eur J Cancer. 62:132–137. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Freites-Martinez A, Santana N,
Arias-Santiago S and Viera A: Using the common terminology criteria
for adverse events (CTCAE-Version 5.0) to evaluate the severity of
adverse events of anticancer therapies. Actas Dermosifiliogr (Engl
Ed). 112:90–92. 2021.(In English, Spanish). View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Roth JA, Fossella F, Komaki R, Ryan MB,
Putnam JB Jr, Lee JS, Dhingra H, De Caro L, Chasen M, McGavran M,
et al: A randomized trial comparing perioperative chemotherapy and
surgery with surgery alone in resectable stage IIIA non-small-cell
lung cancer. J Natl Cancer Inst. 86:673–680. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rosell R, Gómez-Codina J, Camps C, Javier
Sánchez J, Maestre J, Padilla J, Cantó A, Abad A and Roig J:
Preresectional chemotherapy in stage IIIA non-small-cell lung
cancer: A 7-year assessment of a randomized controlled trial. Lung
Cancer. 26:7–14. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nagai K, Tsuchiya R, Mori T, Tada H,
Ichinose Y, Koike T and Kato H; Lung Cancer Surgical Study Group of
the Japan Clinical Oncology Group, : A randomized trial comparing
induction chemotherapy followed by surgery with surgery alone for
patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209).
J Thorac Cardiovasc Surg. 125:254–260. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mattson KV, Abratt RP, ten Velde G and
Krofta K: Docetaxel as neoadjuvant therapy for radically treatable
stage III non-small-cell lung cancer: A multinational randomised
phase III study. Ann Oncol. 14:116–122. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Uprety D, Mandrekar SJ, Wigle D, Roden AC
and Adjei AA: Neoadjuvant immunotherapy for NSCLC: Current concepts
and future approaches. J Thorac Oncol. 15:1281–1297. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhong WZ, Chen KN, Chen C, Gu CD, Wang J,
Yang XN, Mao WM, Wang Q, Qiao GB, Cheng Y, et al: Erlotinib versus
gemcitabine plus cisplatin as neoadjuvant treatment of stage
IIIA-N2 EGFR-Mutant non-small-cell lung cancer (EMERGING-CTONG
1103): A Randomized phase II study. J Clin Oncol. 37:2235–2245.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kang J, Zhang C and Zhong WZ: Neoadjuvant
immunotherapy for non-small cell lung cancer: State of the art.
Cancer Commun (Lond). 41:287–302. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ling Y, Yang Y, Lu N, You QD, Wang S, Gao
Y, Chen Y and Guo QL: Endostar, a novel recombinant human
endostatin, exerts antiangiogenic effect via blocking VEGF-induced
tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem
Biophys Res Commun. 361:79–84. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhai Y, Ma H, Hui Z, Zhao L, Li D, Liang
J, Wang X, Xu L, Chen B, Tang Y, et al: HELPER study: A phase II
trial of continuous infusion of endostar combined with concurrent
etoposide plus cisplatin and radiotherapy for treatment of
unresectable stage III non-small-cell lung cancer. Radiother Oncol.
131:27–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
An J and Lv W: Endostar (rh-endostatin)
versus placebo in combination with vinorelbine plus cisplatin
chemotherapy regimen in treatment of advanced non-small cell lung
cancer: A meta-analysis. Thoracic Cancer. 9:606–612. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bao Y, Peng F, Zhou QC, Yu ZH, Li JC,
Cheng ZB, Chen L, Hu X, Chen YY, Wang J, et al: Phase II trial of
recombinant human endostatin in combination with concurrent
chemoradiotherapy in patients with stage III non-small-cell lung
cancer. Radiother Oncol. 114:161–166. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rong B, Yang S, Li W, Zhang W and Ming Z:
Systematic review and meta-analysis of Endostar (rh-endostatin)
combined with chemotherapy versus chemotherapy alone for treating
advanced non-small cell lung cancer. World J Surg Oncol.
10:1702012. View Article : Google Scholar : PubMed/NCBI
|
